SCHEMBL6897548

SCHEMBL6897548

C#Cc1ccc(-c2ccccc2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.46
SLC6A4 P31645 3/20 0.46
SLC6A2 P23975 1/20 0.40
ACHE P22303 1/20 0.40
GABRA1 P14867 3/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA5 P31644 3/20 0.39
GABRA2 P47869 3/20 0.39
GABRA6 Q16445 3/20 0.39
GABRA3 P34903 2/20 0.39
GABRA4 P48169 1/20 0.39
SCN1A P35498 5/20 0.37
SCN2A Q99250 5/20 0.37
SCN3A Q9NY46 5/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
BRS3 P32247 1/20 0.36
GABRB2 P47870 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL539759 0.86 SLC6A3 (0.46) SLC6A3SLC6A4SLC6A2ACHESCN1A
SCHEMBL9531321 0.83 BCAT2 (0.52) SLC6A3SLC6A4SLC6A2SCN1ASCN2A
SCHEMBL29389473 0.83 BCAT2 (0.52) SLC6A3SLC6A4SLC6A2SCN1ASCN2A
SCHEMBL517 0.82 SLC6A3 (0.50) SLC6A3SLC6A4SLC6A2ACHESCN1A
SCHEMBL1665535 0.82 SLC6A3 (0.49) SLC6A3SLC6A4SLC6A2ACHEGABRA1
SCHEMBL6900241 0.81 SLC6A3 (0.68) SLC6A3SLC6A4SLC6A2ACHESCN1A
SCHEMBL9373323 0.81 SLC6A3 (0.49) SLC6A3SLC6A4SLC6A2ACHESCN1A
Bromomethane SCHEMBL7011845 0.80 SLC6A3 (0.50) SLC6A3SLC6A4SLC6A2SCN1ASCN2A
Methylamine SCHEMBL28010440 0.80 BCAT2 (0.53) SLC6A3SLC6A4SLC6A2SCN1ASCN2A
SCHEMBL3558536 0.79 SLC6A3 (0.48) SLC6A3SLC6A4SLC6A2ACHESCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216970-B2 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-12-22 US disclosed
US-20150105392-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-04-16 US disclosed
US-8946233-B2 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-02-03 US disclosed
US-20140135333-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS THERAVANCE, INC. (US) 2014-05-15 US disclosed
US-8664227-B2 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents THERAVANCE, INC. (US) 2014-03-04 US disclosed
US-20130267539-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS THERAVANCE, INC. (US) 2013-10-10 US disclosed
US-8481549-B2 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents THERAVANCE, INC. (US) 2013-07-09 US disclosed
US-20110178101-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS THERAVANCE BIOPHARMA R&D IP, LLC 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178101-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS REN, AGTR1, AGTR2 SLC6A3 372/4885SLC6A4 248/4885SLC6A2 343/4885
US-20140135333-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS REN, AGTR1, AGTR2 SLC6A3 372/4885SLC6A4 248/4885SLC6A2 343/4885
US-20130267539-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS REN, AGTR1, AGTR2 SLC6A3 372/4885SLC6A4 248/4885SLC6A2 343/4885
US-20150105392-A1 DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS REN, AGTR1, AGTR2 SLC6A3 372/4885SLC6A4 248/4885SLC6A2 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.